

# Preliminary Studies on the Expression and Purification of Functionally Active Recombinant Plasmepsin 9 from *Plasmodium falciparum*

Folasade M. Olajuyigbe<sup>1,2\*</sup>, Nathan E. Goldfarb<sup>1</sup> and Ben M. Dunn<sup>1</sup>

<sup>1</sup>Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, FL 32610-0245, USA

<sup>2</sup>Department of Biochemistry, Federal University of Technology, Akure 340001, Nigeria

## ABSTRACT

**Aim:** Plasmepsins, a group of homologous aspartic proteinases are attractive drug targets against malaria. Plasmepsin 9 (PM9) expressed in the blood stage of malaria life cycle with unknown function has been strongly considered as a potential target however, recombinant expression of active PM9 for biochemical and structure-activity analysis of the enzyme has been very challenging. This paper presents preliminary report on the expression and purification of active recombinant plasmepsin 9 from *Plasmodium falciparum*.

**Place and Duration of Study:** Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, Florida between November 2011 and October, 2012.

**Methodology:** The plasmid of truncated proenzyme (proP<sub>f</sub>PM9) from *Plasmodium falciparum* was expressed in *Escherichia coli* Rosetta 2(DE3)pLysS competent cells. The protein was purified from inclusion bodies using combination of cation exchange and gel filtration chromatography. The expression and purification fractions were subjected to SDS-PAGE. The zymogen was activated to produce mature form of active recombinant P<sub>f</sub>PM9. Catalytic activity test of P<sub>f</sub>PM9 was determined using a chromogenic substrate, Lys-Pro-Ile-Glu-Phe-Nph\*Arg-Leu (RS6). Substrate hydrolysis was examined from substrate cleavage scan.

**Results:** SDS-PAGE confirmed the expression and purification of truncated proenzyme (proP<sub>f</sub>PM9) with molecular weight of approximately 54 kD. Kinetic assays showed that the purified P<sub>f</sub>PM9 was active. The hydrolytic activity of P<sub>f</sub>PM9 on RS6 was confirmed by a shift in absorbance peak from 280 nm to 272 nm at the end of assay reactions.

**Conclusion:** Protocols for successful expression and purification of active recombinant plasmepsin 9 in *E.coli* have been established in this preliminary report. These will aid production of sufficient yield of P<sub>f</sub>PM9 for detailed kinetic and structural characterization of the enzyme and development of future inhibitors against malaria.

**Keywords:** Expression; malaria; plasmepsin 9; *Plasmodium falciparum*; purification; recombinant

\* Tel.: +234-816-458-4482

E-mail address: folajuyi@futa.edu.ng.

## 1. INTRODUCTION

Malaria remains the most prevalent life threatening disease of global significance and a major cause of high infant mortality in over hundred endemic nations across the globe. There are several hundred million clinical cases of malaria annually resulting in about one million deaths, primarily, children [1,2]. Parasites of the genus *plasmodium* cause the disease by degrading human hemoglobin as a source of amino acids for their growth and maturation and the disease is transmitted by *Anopheles* mosquitoes [3]. Of the four human species, *Plasmodium falciparum* is by far the most deadly form and is responsible for the majority of malaria related deaths [4,5]. Malaria prevention and treatment currently relies on vector control and chemotherapy. The spread of parasite-drug resistance, particularly to inexpensive drugs, is thus a significant concern. Chloroquine resistance in the most pathogenic species, *Plasmodium falciparum*, is now almost universal and the declining efficacy of affordable antimalarial drugs, such as sulfadoxine-pyrimethamine is well documented [6]. Hence, novel anti-malarial drug targets are urgently needed to battle these variants.

Hemoglobin degradation is initiated by plasmepsins (PMs), a sub-group of 10 aspartyl proteases defined in the *P.falciparum* genome [4], which have been strongly considered as potential anti-malaria drug targets. The PM proteins were initially discovered by identifying enzymes from the hemoglobin digestion pathway [7]. Four PMs (PM1, PM2 and PM4 and HAP) are expressed in the erythrocytic stages of the lifecycle of *P.falciparum* [8-10] and are localized in the food vacuole [11]. PM5 is an integral membrane protein of the endoplasmic reticulum suggesting a role in protein processing within the parasite [12]. The functions of the remaining PMs 6–10 are unknown but the expression of PMs 5, 9 and 10 occurs in the blood stages of the malaria life cycle [9-11]. Plm5, Plm9 and Plm10 are expressed concurrently with PM1 to PM4 but are not transported to the digestive vacuole (DV). Recently, it has been reported that PM5 licenses *Pf* proteins for export into the host erythrocyte, therefore, it is essential for parasite viability [13]. The remaining PMs (PM6, PM7, PM8) are not expressed during the intraerythrocytic stage [11].

For several years, the structure-based drug design of antimalarial compounds targeting *P. falciparum* DV plasmepsin inhibition has received much attention due to their potential biomedical use [14]. However, a recent study showed that a wide range of previously characterized aspartic protease inhibitors exert their antimalarial activities primarily on one or more non-DV plasmepsins and secondarily on the DV plasmepsins [15]. This finding indicates the relevance in the intraerythrocytic stage of the non-DV plasmepsins as PM5 [13], PM9, and PM10 could be novel drug targets against malaria although their structures have not been solved yet. Up to date, there is scarcity of information on expression and purification of functionally active PM9 and PM10 which is an important prerequisite for proteins to be crystallized and structures determined through X-ray crystallography [16].

Heterologous expression of recombinant plasmodial proteins in *E. coli* is fraught with difficulties as reflected by the paucity of plasmodial protein structures in the Protein Data Bank (PDB, ~250), when compared to the approximately 50,000 protein structures available in the PDB [17]. A variety of factors contribute to make the heterologous expression of *P. falciparum* proteins challenging, some of which include higher molecular weight (> 56 kDa), greater protein disorder, more basic isoelectric point (pI), and lack of homology to *E. coli* proteins ) [18]. The full sequence of proenzyme *Pf*PM9 is made up of 627 amino acids long with molecular weight of 74.18 kDa (UniProtKB/TrEMBL accession number: Q8ILG2) [19], which is responsible for the hurdles encountered in expressing it in the full sequence form.

The production of active recombinant *PfPM9* has been very challenging, we report here for the first time, the expression of a truncated proenzyme (pro*PfPM9*) from *Plasmodium falciparum* in *Escherichia coli* and the activation of the zymogen to produce an active recombinant (*PfPM9*).

## 2. MATERIAL AND METHODS

### Bacterial Strains and Plasmids

*E. coli* strains used in this study were *Escherichia coli* Rosetta 2 (DE3) pLysS Competent Cells and pET3a plasmids were purchased from Novagen. Antibiotics were from Sigma and electrophoresis reagents were obtained from BioRad.

### Expression of pro*PfPM9*

A truncated version of proenzyme *PfPM9* (pro*PfPM9*) was provided as earlier done for *PfPM1* and *PfPM4* [23, 24]. The plasmids were transformed into *Escherichia coli* Rosetta 2 (DE3)pLysS competent cells (Novagen). Cultures of transformed *E. coli* strain Rosetta 2 (DE3)pLysS harbouring the recombinant pET3a plasmids were grown overnight at 37°C in fresh Luria-Bertani (LB) medium overnight in a shaking incubator at 200 rpm. The culture was used to inoculate fresh 1 L LB medium (2% inoculation) containing ampicillin (50 µg/ml) and chloramphenicol (34 µg /ml) as selection antibiotics. This was incubated at 37°C, 200 rpm until the OD<sub>600</sub> reached 0.7 (exponential growth phase of cells). Expression was induced by adding 1 ml of 1M isopropyl β-D-1-thiogalactopyranoside (IPTG) to the 1 L LB expression culture (final concentration of 1 mM). This was incubated at 37°C, 200 rpm for 3 hours. Cells were harvested by centrifugation at 4000 rpm for 20 minutes at 4 °C.

### Inclusion bodies extraction and preparation

Cell pellets were thawed on ice and suspended in ice cold buffer 1 (0.01 M Tris-HCl, pH 8.0, 0.02 M MgCl<sub>2</sub>, 0.005 M CaCl<sub>2</sub>) at 4.2 ml/g wet cell pellet. Cells were lysed via French Pressure Cell at 1000 psi for 4 times keeping the lysed cells on ice. DNase 1 was added to lysed cell suspension to a final concentration of 80 units/ml. The suspension was gently swirled and left at room temperature for 20 minutes. 10 ml of lysate was laid on 10 ml of 27% (w/v) sucrose solution in 30 ml Corex tubes and centrifuged at 12000g, 4 °C for 45 minutes. An aliquot of supernatant was saved for SDS-PAGE. Each pellet obtained was suspended in 10 ml of buffer 2 (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 2 mM β-mercaptoethanol (BME), 100 mM NaCl). The suspension was again laid on 10 ml of 27% (w/v) sucrose solution in 30 ml Corex tubes and centrifuged at 12000g, 4 °C for 45 minutes. An aliquot of supernatant was saved for SDS-PAGE. Each pellet obtained was suspended in 10 ml buffer 3 (50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 2.5 mM BME, 0.5 % Triton X-100). Suspension was centrifuged at 12 000g, 4 °C for 15 minutes. An aliquot of supernatant was stored for SDS-PAGE. Pellet was suspended buffer 4 (50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 2.5 mM BME). Suspension was transferred into pre-weighed centrifuge tubes and spun at 12000g, 4 °C for 15 minutes. An aliquot of supernatant was again stored for SDS-PAGE. The weight of the wet inclusion bodies (IB) pellet was determined. IB pellet was suspended in TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) to a final concentration of 100 mg/ml and stored at – 80 °C until ready for use.

### Refolding and purification of pro*PfPM9*

8 M urea solution was freshly prepared. For every 10 ml of urea solution, 1 gm of Amberlite ion exchange resin was added (10 ml urea solution/g Amberlite resin). This was stirred for 60 minutes at room temperature to deionize urea. The resin was removed by filtering the urea solution containing the resin. Sodium phosphate was added to the filtered urea solution to give final concentration of 50 mM and NaCl was added to a final concentration of 500 mM. The buffer was made up to final volume with distilled water and pH adjusted to 7.5. This was

filtered and referred to as IB solubilization buffer. IB stored in TE buffer at -80 °C was thawed on ice and centrifuged at 12000 g, 4 °C for 15 minutes. Solubilization buffer (Urea-phosphate buffer pH 7.5) was added to IB pellet at 1 ml 8M urea / 68 mg IB. Denaturing/solubilization of IB was carried out at room temperature for 2 hours. This allowed complete extraction of proP $\beta$ PM9. The solution was centrifuged at 13000g, 4 °C for 30 minutes. Supernatant was obtained and an aliquot of supernatant was kept for SDS-PAGE. Protein concentration was determined by Bradford method [25]. The supernatant was dialyzed in 20 mM Tris-HCl, pH 8.0 at 4 °C (X 100 volume of protein solution) with stirring and three changes of buffer. The first buffer change was after 4 hours. The buffer was exchanged for fresh 20 mM Tris-HCl, pH 8.0 and left to dialyze overnight. The buffer was changed the next morning making the third change of buffer and left to dialyze finally for 4 hours. The resulting dialysate contained refolded proP $\beta$ PM9 and was centrifuged at 13000g, 4 °C for 30 minutes. An aliquot was stored for SDS-PAGE, protein concentration determination and P $\beta$ PM9 activity assay. For the purification to be carried out on a cation exchanger, the dialysate in Tris-HCl buffer was diluted 10X with cold 20 mM Tris-HCl, pH 8.0 buffer before further dialysis in cold 50 mM MES, pH 6.5 buffer at 4 °C (X 20 volume of protein solution) with two buffer changes, each for 3 hours. The resulting dialysate was centrifuged at 13000g, 4 °C for 30 minutes. An aliquot was stored for SDS-PAGE, protein concentration determination and enzyme activity assay as described earlier. The dialysate in 50 mM MES, pH 6.5 buffer containing the refolded was stored at 4 °C.

#### **Purification of proP $\beta$ PM9 on cation exchange chromatography using HiTrap SP column**

The HiTrap SP column was first washed with 25 ml of start buffer (50 mM MES buffer pH 6.5) at 3 ml/min. The column was again washed with 25 ml of elution buffer (50 mM MES buffer pH 6.5, 1 M NaCl). Final equilibration was done by washing the column with 100 ml of start buffer (50 mM MES buffer pH 6.5). The refolded protein in 50 mM MES pH 6.5 buffer was loaded onto the SP column. The flow through was collected and tested for presence of protein. Purified protein was eluted with a salt gradient up to 1 M NaCl on Amersham Pharmacia FPLC. Fractions collected were tested for protein at OD<sub>280</sub> and chromatogram of OD<sub>280</sub> was plotted against eluted fraction volume to identify peak fractions. The NaCl gradient (0-100%) was also plotted on the chromatogram to determine the NaCl gradient-protein elution profile. Aliquots from fractions containing protein were run on SDS-PAGE and catalytic assay were performed on the fractions. Peak fractions showing P $\beta$ PM9 activity were found to be eluted with the 450 mM NaCl gradient. Purified fractions containing active P $\beta$ PM9 were pooled and subjected to gel filtration on Superdex 75. Purified fractions were stored at 4 °C.

#### **Gel filtration chromatography of proP $\beta$ PM9 on Superdex™ 75**

The Superdex™ 75 column was first calibrated using standard proteins with known molecular weights before carrying out gel filtration on the partially purified proP $\beta$ PM9. The pooled fraction from cation exchange chromatography was concentrated to a smaller volume ( $\leq$  2 ml) before loading on Superdex 75 column with elution buffer, 50 mM MES pH 6.5, 450 mM NaCl. Fractions collected were tested for protein at OD<sub>280</sub> and chromatogram of OD<sub>280</sub> was plotted against fraction number to identify peak fractions. SDS-PAGE was run on peak fractions and catalytic assay was also performed to determine the activity of the pure proP $\beta$ PM9. Protein peak fractions with active P $\beta$ PM9 were pooled together and the total volume was recorded. Protein concentration was determined by Bradford method [25].

#### **Activation and assay of P $\beta$ PM9**

The ProP $\beta$ PM9 was activated by incubating it at 37 °C for 20 minutes in 50 mM sodium acetate buffer, pH 4.5. The pre-incubation time allows zymogen conversion to the mature form which shows catalytic activity. Plasmeprin 9 kinetic assay was done using the

chromogenic substrate, Lys-Pro-Ile-Glu-Phe-Nph\*Arg-Leu (RS6) where \* represents cleavage site. Catalytic activity was confirmed by monitoring the decrease in average absorbance from 280 to 272 nm [26] using a Cary 50 Bio UV-visible spectrophotometer (Varian). Stock peptide solutions were made in 10% formic acid and 90% distilled water. Reactions were carried out in 50 mM sodium acetate buffer, pH 4.5 at 37 °C. The total reaction volume was 250 µl. The reaction mixture had a 50 µM substrate solution. Reaction was initiated when the mature *PfPM9* was added to the substrate solution. The substrate cleavage reaction was monitored in a Cary50 UV/Visible spectrophotometer by the decrease in average absorbance from 302–410 nm.


### 3. RESULTS AND DISCUSSION

The plasmid vector used in cloning of truncated *proPfPM9* gene was pET3a which contained a T7-tagged sequence. The expressed truncated *proPfPM9* protein contains a T7 tag on its amino-terminal end (Scheme 1). The expressed zymogen (Figure 1a) accumulated in the form of inclusion bodies in *E. coli* (Figure 1b). A total of 1.47 g of purified inclusion bodies was obtained from 4 L of expression culture (data not shown). The inclusion bodies were solubilized in 8 M Urea-phosphate buffer pH 7.5 and the supernatant obtained contained the unfolded *proPfPM9* as confirmed by SDS-PAGE (Figure 1b). The subjected to refolding procedure described under experimental section. It was observed that refolding *proPfPM9* by dialysis in 20 mM Tris-HCl pH 8.0 yielded 94% of soluble protein. The soluble dialysate was the refolded *proPfPM9* as revealed by the SDS-PAGE (Figure 1c). The pI of *proPfPM9* is 9.15 (Scheme 1) so, the initial purification of the refolded protein was by cation exchange chromatography. The refolded *proPfPM9* was dialysed in 50 mM MES buffer pH 6.5. Dialysis of the refolded *proPfPM9* directly in MES buffer pH 6.5 resulted in 83 % precipitates of the refolded protein (data not shown). This could be due to the very high concentration of protein in the Tris-HCl buffer (21 mg/ml). The refolding protocol was optimized by 10X dilution of refolded protein solution in 20 mM Tris-HCl buffer, pH 8.0 before dialysis in 50 mM MES buffer pH 6.5 (Table 1).

**M A S M T G G Q Q M G R G S N H M N K I K D E K Y K Q E Y E E E K E I Y D N T N T S**  
**Q E K N E T N N E Q N L N I N L I N N D K V T L P L Q Q L E D S Q Y V G Y I Q I G T P P**  
**Q T I R P I F D T G S T N I W I V S T K C K D E T C L K V H R Y N H K L S S S F K Y Y E**  
**P H T N L D I M F G T G I I Q G V I G V E T F K I G P F E I K N Q S F G L V K R E K A S**  
**D N K S N V F E R I N F E G I V G L A F P E M L S T G K S T L Y E N L M S S Y K L Q H**  
**N E F S I Y I G K D S K Y S A L I F G G V D K N F F E G D I Y M F P V V K E Y Y W E I H**  
**F D G L Y I D H Q K F C C G V N S I V Y D L K K K D Q E N N K L F F T R K Y F R K N K**  
**F K T H L R K Y L L K K I K H Q K K Q K H S N H K K K L N K K K N Y L I F D S G T S**  
**F N S V P K D E I E Y F F R V V P S K K C D D S N I D Q V V S S Y P N L T Y V I N K M P**  
**F T L T P S Q Y L V R K N D M C K P A F M E I E V S S E Y G H A Y I L G N A T F M R Y**  
**Y Y T V Y R R G N N N N S S Y V G I A K A V H T E**

**Scheme 1. Schematic representation of the amino acid sequence of translated N and C-terminal *proPfPM9* Truncation** (Red = T7 tag from pET3a vector, Green = beginning and end of truncated *proPfPM9*) with theoretical pI/Mw: 9.15 / 53606.

227



228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248


249

250

251


**Fig. 1. Expression of proPfPM9 from *E.coli* Rosetta 2(DE3)pLysS. on 10% SDS-PAGE.**  
a). showing non-induced expression culture (1) and IPTG induced expression culture (2). (b) Inclusion bodies preparation showing soluble fractions of lysate (1-4). (c) Solubilized inclusion bodies in Urea-phosphate buffer pH 7.5 (1), refolded proPfPM9 in 20 mM Tris-HCl pH 8.0 buffer (2) and 10X dilution of refolded proPfPM9 dialysed in 50 mM MES, pH 6.5 buffer (3). Bands of proPfPM9 highlighted in red boxes.

An average of 0.64 mg of purified activatable PfPM9 zymogen was obtained from 4 L of cell culture (Table 1). The yield appears low but very encouraging when compared with first reported yield of proPfPM1 [20], which was 0.9 mg of purified activatable PfPM1 zymogen from 14 L of cell culture. As earlier reported for processing of proplasmepsins 1, 2 and 4 which required acidic conditions in the range of 4.0 – 5.0 to become catalytically active [21-23], the refolded proPfPM9 was also activated to the mature enzyme following incubation at pH 4.5. Spectrophotometric assay procedure described under experimental section using chromogenic substrate, RS6 (Lys-Pro-Ile-Glu-Phe-Nph\*Arg-Leu) was followed. The kinetic assay showed that the refolded PfPM9 was active (Figures 2a and 2b). Confirmation of active PfPM9 was made from substrate cleavage scan at the end of the assay reaction which showed hydrolysis of RS6 by shift of absorbance peak from 280 nm to 272 nm (Figures 2c and 2d).



**Fig. 2. Kinetic assays on PfPM9** (a). Velocity of hydrolysis of RS6 by refolded PfPM9 in 20 mM Tris-HCl pH 8 ( $4.7 \times 10^{-4}$  AU/sec). (b) Velocity of hydrolysis of RS6 by 10X diluted PfPM9 in 50 mM MES pH 6.5 ( $0.74 \times 10^{-4}$  AU/sec). (c.) Substrate cleavage by PfPM9 showing a shift in absorbance peak from 280 nm to 272 nm (in green). (d). Substrate cleavage by positive control, cathepsin D (in green)

The refolded proP<sub>1</sub>PM9 was purified from the soluble dialysate by FPLC using cation exchange (Figures 3a and b) and gel filtration chromatography (Figures 3d and e) as described under experimental section. The SDS – PAGE of peak fractions from both purification techniques (Figures 3c and f) confirm bands of pure proP<sub>1</sub>PM9 (approx. 54 kD).



**Fig. 3. Purification and activity of P<sub>1</sub>PM9.** (a) Chromatogram of proP<sub>1</sub>PM9 on cation-exchange chromatography using HiTrap SP column. (b).Chromatogram of proP<sub>1</sub>PM9 vs activity of eluted fractions. (c). SDS – PAGE of peak fractions from cation exchange chromatography (d). Chromatogram of proP<sub>1</sub>PM9 on Superdex™ 75 gel filtration chromatography. (e). Velocity of hydrolysis of RS6 by unconcentrated pooled P<sub>1</sub>PM9 peak fraction from gel filtration chromatography ( $5.9 \times 10^{-4}$  AU/sec). (f). SDS – PAGE of peak fractions from gel filtration chromatography.

**Table 1.** Purification table of recombinant proP<sub>1</sub>PM9 from 4 L expression

Step	Volume (mL)	Total protein (mg)	Total activity ( $\times 10^{-4}$ AU/sec)	Specific activity (units/mg)	Purification fold	Yield (%)
Refolding (Dialysis in 20 mM Tris-HCl pH 8)	20	462.6	11844	25.6	1	100
Dialysis in 50 mM MES pH 6.5	202	385.5	8282	21.48	1	70
SP-Cation Exchange chromatography	8	1.57	633.1	403.2	16	5.3
Superdex 75 Gel filtration chromatography	6	0.64	412.2	644.06	25	3.5



#### 4. CONCLUSION

We have successfully expressed and purified functionally active recombinant proP<sub>1</sub>PM9. This preliminary report provides good background to further optimize protocols for improved yield of proP<sub>1</sub>PM9 for detailed kinetic and structural characterization of the enzyme.

#### ACKNOWLEDGEMENTS

This work was supported by NIH MERIT award (R37 grant) to Prof Ben M. Dunn and Schlumberger Foundation FFTF 2011 award to Dr. Folasade M. Olajuyigbe.

#### REFERENCES

1. WHO, Malaria Fact Sheet, 2012;94.
2. Bhaumik P, Horimoto Y, Xiao H, Miura T, Hidaka K, Kiso Y et al. Crystal structures of the free and inhibited forms of plasmepsin I (PMI) from *Plasmodium falciparum*. J Struct Biol. 2011;175:73–84.
3. Asojo OA, Gulnik SV, Afonina E, Yu B, Ellman JA, Haque TS et al. Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from *Plasmodium falciparum*. J Mol Biol 2003;327:173–81.
4. Coombs GH, Goldberg DE, Klemba M, Berry C, Kay J, Mottram JC. Aspartic proteases of *Plasmodium falciparum* and other parasitic protozoa as drug targets. Trends Parasitol. 2001;17:532–37.
5. Beyer BB, Johnson JV, Chung AY, Li T, Madabushi A, Agbandje-McKenna M et al. Active-site specificity of digestive aspartic peptidases from the four species of *Plasmodium* that infect humans using chromogenic combinatorial peptide libraries. Biochemistry 2005;44:1768–79.
6. Skinner-Adams TS, McCarthy JS, Gardiner DL, Andrews KT. HIV and malaria co-infection: interactions and consequences of chemotherapy. Trends in Parasitol. 2008; 24:264–71.
7. Goldberg DE, Slater AF, Beavis R, Chait B, Cerami A, Henderson GB. Hemoglobin degradation in the human malaria pathogen *Plasmodium falciparum*: a catabolic pathway initiated by a specific aspartic protease. J Exp Med. 1991;173:961–69.
8. Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, Haynes JD et al. A proteomic view of the *Plasmodium falciparum* life cycle. Nature 2002;419:520–26.
9. Bozdech Z, Llinas M, Pulliam BL, Wong ED, Zhu J, DeRisi JL. The transcriptome of the intraerythrocytic developmental cycle of *Plasmodium falciparum*. PLoS Biol. 2003;1:E5.
10. Le Roch KG, Zhou Y, Blair PL, Grainger M, Moch JK, Haynes JD et al. Discovery of gene function by expression profiling of the malaria parasite life cycle. Science, 2003; 301:1503–08.
11. Banerjee R, Liu J, Beatty W, Pelosof L, Klemba M, Goldberg DE. Four plasmepsins are active in the *Plasmodium falciparum* food vacuole, including a protease with an active-site histidine. Proc Natl Acad Sci USA. 2002;99:990–95.
12. Klemba M, Goldberg DE. Characterization of plasmepsin V, a membrane-bound aspartic protease homolog in the endoplasmic reticulum of *Plasmodium falciparum*. Mol Biochem Parasitol. 2005;143:183–91.

- 332 13. Russo I, Babbitt S, Muralidharan V, Butler T, Oksman A, Goldberg DE. Plasmepsin  
333 V licenses *Plasmodium* proteins for export into the host erythrocyte. *Nature*  
334 2010;463:632-36.
- 335 14. Gil LA, Valiente PA, Pascutti PG, Pons T. Computational perspectives into  
336 plasmepsins structure-function relationship: implications to inhibitors design. *J Trop*  
337 *Med.* 2011; 2011;657483.
- 338 15. Moura PA, Dame JB, Fidock DA. Role of *Plasmodium falciparum* digestive vacuole  
339 plasmepsins in the specificity and antimalarial mode of action of cysteine and  
340 aspartic protease inhibitors. *Antimicrob Agents Chemother.* 2009;53:4968–78.
- 341 16. Olajuyigbe FM, Demitri N, Geremia S. Investigation of 2-fold disorder of inhibitors  
342 and relative potency by crystallizations of HIV-1 protease in ritonavir and saquinavir  
343 mixtures. *Cryst Growth Des.* 2011;11:4378-85.
- 344 17. Birkholtz L, Blatch G, Coetzer TL, Hoppe HC, Human E, Morris EJ et al.  
345 Heterologous expression of plasmodial proteins for structural studies and functional  
346 annotation. *Malaria J.* 2008;7:197
- 347 18. Mehlin C, Boni E, Buckner FS, Engel L, Feist T, Gelb MH et al. Heterologous  
348 expression of proteins from *Plasmodium falciparum*: Results from 1000 genes. *Mol*  
349 *Biochem Parasitol.* 2006;148:144-60.
- 350 19. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW et al. Genome  
351 sequence of the human malaria parasite *Plasmodium falciparum*. *Nature*  
352 2002;419:498–511.
- 353 20. Moon RP, Tyas L, Certa U, Rupp K, Bur D, Jacquet C et al. Expression and  
354 characterization of plasmepsin I from *Plasmodium falciparum*. *Eur J Biochem.* 1997;  
355 244:552–60.
- 356 21. Tyas L, Gluzman I, Moon RP, Rupp K, Westling J, Ridley RG et al. Naturally-  
357 occurring and recombinant forms of Plasmepsins I and II from the human malaria  
358 parasite *Plasmodium falciparum* *FEBS Lett.* 1999;454:210–14.
- 359 22. Boss C, Corminboeuf O, Grisostomi C, Meyer S, Jones A, Prade L. Achiral, cheap,  
360 and potent inhibitors of plasmepsins I, II, and IV. *ChemMedChem* 2006;1:1341-45.
- 361 23. Liu P, Marzahn MR, Robbins AH, Gutierrez-de-Teran H, Rodriguez D, McClung S.  
362 Recombinant plasmepsin 1 from the human malaria parasite *Plasmodium*  
363 *falciparum*: enzymatic characterization, active site. *Biochemistry*, 2009;48:4086–99.
- 364 24. Wyatt DM, Berry C. Activity and inhibition of plasmepsin IV, a new aspartic  
365 proteinase from the malaria parasite, *Plasmodium falciparum* *FEBS Letters*,  
366 2002;513:159–62.
- 367 25. Bradford MM. A rapid and sensitive method for the quantitation of microgram  
368 quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem.*  
369 1976;72:248-54.
- 370 26. Dunn BM, Scarborough PE, Davenport R, Swietnicki W. Analysis of proteinase  
371 specificity by studies of peptide substrates: The use of UV and fluorescence  
372 spectroscopy to quantitate rates of enzymatic cleavage. *Methods Mol Biol.*  
373 1994;36:225-43

374  
375